放射性粒子植入联合恩度治疗原发性肝癌的临床观察  

The Value of ^(125)I Radioactive Seeds Implantation Combined with Endostar for Primary Hepatic Carcinoma

作　　者：朱莹[1] 张丽娟[1] 

机构地区：[1]郑州大学附属郑州中心医院,河南郑州450007

出　　处：《中国医学创新》2014年第8期1-3,共3页Medical Innovation of China

摘　　要：目的:探讨放射性粒子植入联合恩度治疗原发性肝癌的临床疗效。方法:60例原发性肝癌病例,均行放射性粒子植入治疗,其中30例患者术后加用恩度(重组人血管内皮抑素),作为恩度组,另30例患者术后常规对症支持治疗,作为正常对照组。随访2个月,检测血清血管内皮生长因子(VEGF)浓度,比较两组患者临床缓解率及VEGF水平变化。结果:恩度组临床缓解率高,VEGF浓度明显降低,与对照组比较差异有统计学意义(P<0.05)。结论:放射性粒子植入联合恩度是治疗原发性肝癌的有效方法,可以提高疗效。Objective： To investigate the therapeutic effect of 125I radioactive seeds implantation combined with Endostar in the treatment of primary hepatic carcinoma. Method： 60 primary hepatic earcinoma cases who were accepted radioactive seeds implantation were divided into two groups, one group （ 30 cases ） with Endostar after the implanation, the other group （ 30 eases ） without Endostar. With two months follow-up, the clinical remission and the concentration of vascular endothelial growth factor （ VEGF ） in serum were observed. Moreover, the clinical remission rate and the variation of VEGF were compared between the two groups. Result： The clinical remission rate of the Endostars group was higher than that of the normal control group. The VEGF concentration of the Endostars group was lower than that of the normal control group, the differences were statistically significant （P〈O.05） . Conclusion： The lZ^I radioactive seeds implantation combined with Endostar is an effective method in the treatment of primary hepatic cancer, which can improve curative effect.

关 键 词：碘放射性同位素 恩度 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]